se of new radiopharmaceutical (callede 68-Ga-DOTANOC) for diagnosis of particolar tumors

Active, not recruiting

• Conditions: Tumors od neuroendrocrine origin; MedDRA version: 14.1Level: SOCClassification code 10022891Term: InvestigationsSystem Organ Class: 10022891 - Investigations; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2011-001724-38-IT
• Lead Sponsor: OSPEDALE SACRO CUORE-DON CALABRIA

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-03-01
• Last Update Posted: 20 March 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Age > 18 years; male or female; tumor of neuroendocrine origine
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 40
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion Criteria

< 18 years; pregnancy; breast-feed; incapable to intend

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified